Similar articles

• Chemotherapeutic options for cisplatin-ineligible patients with advanced carcinoma of the urothelium.

  Vaughn DJ. Vaughn DJ. Cancer Treat Rev. 2008 Jun;34(4):328-38. doi: 10.1016/j.ctrv.2007.12.006. Epub 2008 Feb 8. Cancer Treat Rev. 2008. PMID: 18262363 Review.
• Carboplatin based induction chemotherapy for nonorgan confined bladder cancer--a reasonable alternative for cisplatin unfit patients?

  Mertens LS, Meijer RP, Kerst JM, Bergman AM, van Tinteren H, van Rhijn BW, Horenblas S. Mertens LS, et al. J Urol. 2012 Oct;188(4):1108-13. doi: 10.1016/j.juro.2012.06.018. Epub 2012 Aug 15. J Urol. 2012. PMID: 22901581
• A phase II study of carboplatin in metastatic transitional cell carcinoma of the bladder (a report of the Medical Research Council Working Party on Urological Cancer, Subgroup in Advanced Bladder Cancer).

  [No authors listed] [No authors listed] Eur J Cancer Clin Oncol. 1987 Apr;23(4):375-7. Eur J Cancer Clin Oncol. 1987. PMID: 3301367
• Response of nude mouse-grown human urothelial cancer to cis-diamminedichloroplatinum(II), diammine[1,1-cyclobutanedicarboxylato(2-)-O,O'-platinum], and mitoguazone dihydrochloride.

  Kyriazis AP, Yagoda A, Kyriazis AA, Fogh J. Kyriazis AP, et al. Cancer Res. 1985 May;45(5):2012-5. Cancer Res. 1985. PMID: 3886128
• Systemic therapy of bladder cancer.

  Salem PA. Salem PA. Prog Clin Biol Res. 1984;162B:95-105. Prog Clin Biol Res. 1984. PMID: 6209726 Review. No abstract available.